$86.72 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter

Share on StockTwits

Brokerages predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report sales of $86.72 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings. The lowest sales estimate is $73.16 million and the highest is $93.86 million. Ironwood Pharmaceuticals reported sales of $94.21 million in the same quarter last year, which indicates a negative year-over-year growth rate of 8%. The business is scheduled to announce its next earnings report before the market opens on Wednesday, February 13th.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $304.29 million for the current financial year, with estimates ranging from $289.11 million to $311.92 million. For the next fiscal year, analysts forecast that the firm will report sales of $395.21 million, with estimates ranging from $350.05 million to $474.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Ironwood Pharmaceuticals.

IRWD has been the subject of a number of analyst reports. ValuEngine downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. Credit Suisse Group reiterated a “neutral” rating and issued a $19.00 price target (down from $22.00) on shares of Ironwood Pharmaceuticals in a research report on Wednesday, November 7th. HC Wainwright set a $12.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “sell” rating in a research report on Monday, December 10th. Wells Fargo & Co dropped their price target on shares of Ironwood Pharmaceuticals to $18.50 and set an “outperform” rating for the company in a research report on Thursday, November 1st. Finally, Morgan Stanley set a $11.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $17.28.

Shares of NASDAQ IRWD traded down $0.18 during midday trading on Friday, reaching $13.69. The company’s stock had a trading volume of 101,107 shares, compared to its average volume of 1,380,053. Ironwood Pharmaceuticals has a fifty-two week low of $9.07 and a fifty-two week high of $21.20. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -14.74 and a beta of 1.91.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 89,551 shares of the company’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $12.53, for a total transaction of $1,122,074.03. Following the sale, the chief executive officer now owns 4,726,917 shares of the company’s stock, valued at $59,228,270.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter M. Hecht sold 30,000 shares of the company’s stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $12.66, for a total transaction of $379,800.00. Following the sale, the chief executive officer now directly owns 4,726,917 shares in the company, valued at approximately $59,842,769.22. The disclosure for this sale can be found here. In the last three months, insiders sold 121,551 shares of company stock worth $1,526,814. 7.63% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of IRWD. Trustcore Financial Services LLC bought a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter worth about $1,917,000. Engineers Gate Manager LP acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter worth about $1,761,000. PNC Financial Services Group Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 584.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 116,489 shares of the biotechnology company’s stock worth $2,152,000 after acquiring an additional 99,476 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,324,954 shares of the biotechnology company’s stock worth $227,518,000 after acquiring an additional 377,177 shares during the last quarter. Finally, Alps Advisors Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 23.8% in the 3rd quarter. Alps Advisors Inc. now owns 246,297 shares of the biotechnology company’s stock worth $4,547,000 after acquiring an additional 47,400 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors and hedge funds.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

See Also: Stock Symbol

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply